Li, Haojia http://orcid.org/0000-0001-5000-5334
Bera, Kaustav http://orcid.org/0000-0001-9831-6000
Toro, Paula
Fu, PingFu http://orcid.org/0000-0002-2334-5218
Zhang, Zelin
Lu, Cheng
Feldman, Michael
Ganesan, Shridar
Goldstein, Lori J.
Davidson, Nancy E.
Glasgow, Akisha
Harbhajanka, Aparna
Gilmore, Hannah
Madabhushi, Anant http://orcid.org/0000-0002-5741-0399
Article History
Received: 13 December 2020
Accepted: 25 June 2021
First Online: 6 August 2021
Competing interests
: Dr. Madabhushi is an equity holder in Elucid Bioimaging and in Inspirata Inc. In addition, he has served as a scientific advisory board member for Inspirata Inc, Astrazeneca, Bristol Meyers-Squibb and Merck. Currently he serves on the advisory board of Aiforia Inc. He also has sponsored research agreements with Philips and Bristol Meyers-Squibb. His technology has been licensed to Elucid Bioimaging. He is also involved in a NIH U24 grant with PathCore Inc, and 3 different R01 grants with Inspirata Inc. Dr. Ganesan has consulted for Merck, Roche, Foundation Medicine, Foghorn Therapeutics, Inspirata, Novartis and EQRX. He is also on the Scientific Advisory Board of Silagene. In addition, he has equity in Silagene and Inspirata and research funding from M2Gen. His spouse is an employee of Merck and has equity in Merck. The remaining authors declare no competing interests.